Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Mallinckrodt
Colorcon
Dow
McKinsey

Last Updated: August 13, 2022

Recro Gainesville Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the competitive landscape for RECRO GAINESVILLE, and when can generic versions of RECRO GAINESVILLE drugs launch?

RECRO GAINESVILLE has one approved drug.

There are sixteen US patents protecting RECRO GAINESVILLE drugs.

There are twenty-eight patent family members on RECRO GAINESVILLE drugs in twenty-one countries.

Summary for Recro Gainesville
International Patents:28
US Patents:16
Tradenames:1
Ingredients:1
NDAs:1
Patent Litigation for Recro Gainesville: See patent lawsuits for Recro Gainesville

Drugs and US Patents for Recro Gainesville

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-002 Oct 25, 2013 DISCN Yes No 9,486,451 See Plans and Pricing See Plans and Pricing
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-003 Oct 25, 2013 DISCN Yes No 9,486,451 See Plans and Pricing See Plans and Pricing
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-002 Oct 25, 2013 DISCN Yes No 9,132,096 See Plans and Pricing Y See Plans and Pricing
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-004 Oct 25, 2013 DISCN Yes No 9,713,611 See Plans and Pricing Y See Plans and Pricing
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-004 Oct 25, 2013 DISCN Yes No 9,333,201 See Plans and Pricing See Plans and Pricing
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-001 Oct 25, 2013 DISCN Yes No 10,722,511 See Plans and Pricing See Plans and Pricing
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-004 Oct 25, 2013 DISCN Yes No 9,452,163 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Recro Gainesville

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-002 Oct 25, 2013 6,902,742 See Plans and Pricing
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-005 Oct 25, 2013 6,902,742 See Plans and Pricing
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-001 Oct 25, 2013 6,228,398 See Plans and Pricing
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-003 Oct 25, 2013 6,902,742 See Plans and Pricing
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-005 Oct 25, 2013 6,228,398 See Plans and Pricing
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-004 Oct 25, 2013 6,228,398 See Plans and Pricing
Recro Gainesville ZOHYDRO ER hydrocodone bitartrate CAPSULE, EXTENDED RELEASE;ORAL 202880-006 Oct 25, 2013 6,902,742 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for RECRO GAINESVILLE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, and 50 mg ➤ Subscribe 2014-02-26

International Patents for Recro Gainesville Drugs

Country Patent Number Estimated Expiration
European Patent Office 3191085 See Plans and Pricing
China 107106503 See Plans and Pricing
Canada 2872677 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2014022570 See Plans and Pricing
Mexico 2017003082 See Plans and Pricing
Australia 2015313785 See Plans and Pricing
Japan 6687624 See Plans and Pricing
>Country >Patent Number >Estimated Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Moodys
McKesson
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.